BioMarin is continuing to slim down its pipeline, this time ending work on a preclinical phenylketonuria (PKU) drug once ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

The FDA formally kicked off its quinquennial process to reauthorize the federal user fee legislation that helps fund its ...

A Senate committee has rejected President Donald Trump’s efforts to gouge funding for the National Institutes of Health (NIH) ...

The brain-computer interface developer Synchron has shown that its minimally invasive device can help connect a patient with ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

OrbiMed’s website lists 134 biopharma companies across the firm’s portfolio. Recent investments the firm has participated in ...

Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...

Skin-focused Sirona Biochem is liquidating its R&D subsidiary after a pair of financing deals and a licensing agreement with ...

Despite the recent buzz, the effort to reduce animal testing in favor of NAMs has been underway for years. The VQN falls ...

Baxter saw its stock price plunge by more than 20% after it lowered its revenue projections for the remainder of this year, ...

A new Caribbean company has emerged to enter the increasingly crowded T-cell engager space. | A new Caribbean company has ...